Janet K Yamamoto

Janet K Yamamoto,

Professor, Immunology

Department: Department of Infectious Diseases & Immunology
Business Phone: (352) 294-4145
Business Email: yamamoto@ufl.edu

Accomplishments

Inductee
2015 · Florida Inventors Hall of Fame
Fellow
2014 · National Academy of Inventors (NIA)
Professorship Award
2011 · University of Florida Research Foundation
Faculty Achievement Recognition
2007 · University of Florida
Ad hoc grant reviewer
2006 · Medical Research Council, UK
Regular member, AIDS Immunology & Pathogenesis Study Section
2005-2008 · NIH, NIAID
Pfizer Animal Health Award for Research Excellence
2005 · University of Florida
Ad hoc member, AIDS ARR 2 Study Section
2004 · NIH
Ad hoc grant reviewer
2003-2004 · Medical Research Council, UK
Ad hoc member, Study Section on AIDS K08
2002 · NIH
Honorary member
2002 · Upsilon Chapter of the Society of Phi Zeta
Research Foundation Professorship Award
2002 · University of Florida
International Advisory Committee
2000-2014 · International Feline Retrovirus Research Symposium
Ad hoc member, AIDS ARR 2 Study Section
2000 · NIH
Ad hoc member, Vaccine Special Emphasis Panel (VACC 01, 02, 03, 010)
1998-2005 · NIH
Ad hoc member, Study Section on Small Business and STTR Grants
1998 · NIH, NIMH
Ad hoc team leader, Primate Research Center Site Visit
1998 · NIH, NCRR
Ad hoc member, Primate Research Center Site Visit
1996 · NIH, NCRR
Pfizer Animal Health Award for Research Excellence
1996 · University of Florida
Ad hoc member, Minority Enhancement Program Study Section
1995 · NIH, NIAID
Ad hoc member, Panel on RFA on Blood Brain Barrier in HIV
1995 · NIH, NIMH
Regular member, AIDS & Immunology Study Section (MHAI2)
1994-1998 · NIH, NIHM
Member, Immunology & Microbiology Study Section
1993-1995 · American Heart Association

Research Profile

Dr. Yamamoto has been working in the HIV-1 field since 1984 and is the co-discoverer of feline immunodeficiency virus (FIV, feline counterpart of HIV) and the inventor of the first commercial FIV vaccine (Fel-O-Vax® FIV, sold by Pfizer and Boehringer). Under the leadership of Dr. Murray Gardner (director of CFAR) in 1984, she set up the first HIV-1 laboratory at the University of California, Davis (UCD) which later became the main laboratory of the NIH-funded Center for AIDS Research (CFAR) at UCD. She is the first to publish together with Drs. Francois Barré-Sinousi (Nobelauriate) and Gardner that IFNα and IFNβ suppresses HIV-1 replication but IFNγ enhances HIV-1 replication. Based on her experience in large-scale production of HIV-1 viruses and HIV-1 immunoblots, she also served as the consultant on the second FDA-approved HIV-1 immunoblot by Bio-Rad Laboratories. She has extensive experience in adjuvants for protein vaccines including cytokine (IL12, IL15, IL18, IFNγ) supplement of adjuvants in cats. After the discovery of FIV, her laboratory has focused on the development of FIV vaccine for both prophylaxis and therapeutic uses and FIV infection of cats as the natural small animal model of HIV/AIDS. Her laboratory has been studying the immune mechanism(s) of the protection conferred by prototype and commercial dual-subtype FIV vaccines as an animal model for developing HIV-1 vaccine. Her laboratory has discovered that vaccine-induced T-cell immunity may be more important in prophylactic protection against both homologous-subtype and heterologous-subtype FIV than vaccine-induce antibody immunity. Based on this finding, her laboratory is developing a second-generation FIV vaccine which has no conflict with commercial FIV diagnostics. Her laboratory is also working on identifying T-cell epitopes on HIV for an effective HIV vaccine for prophylaxis and therapy. Yamamoto has had NIH grant for 30 years and the majority of 90 journal/book publications and 32 patent publications are on FIV or HIV-1.

Publications

2019
Immunogenicity and Efficacy of a Novel Multi-Antigenic Peptide Vaccine Based on Cross-Reactivity between Feline and Human Immunodeficiency Viruses.
Viruses. 11(2) [DOI] 10.3390/v11020136. [PMID] 30717485.
2018
Lessons Learned in Developing a Commercial FIV Vaccine: The Immunity Required for an Effective HIV-1 Vaccine.
Viruses. 10(5) [DOI] 10.3390/v10050277. [PMID] 29789450.
2018
Therapeutic Antibody Discovery in Infectious Diseases Using Single-Cell Analysis.
Advances in experimental medicine and biology. 1068:89-102 [DOI] 10.1007/978-981-13-0502-3_8. [PMID] 29943298.
2018
Utilization of Feline ELISpot to Evaluate the Immunogenicity of a T Cell-Based FIV MAP Vaccine.
Methods in molecular biology (Clifton, N.J.). 1808:197-219 [DOI] 10.1007/978-1-4939-8567-8_18. [PMID] 29956186.
2017
Conserved HIV Epitopes for an Effective HIV Vaccine.
Journal of clinical & cellular immunology. 8(4) [DOI] 10.4172/2155-9899.1000518. [PMID] 29226015.
2016
An initial examination of the potential role of T-cell immunity in protection against feline immunodeficiency virus (FIV) infection.
Vaccine. 34(12):1480-8 [DOI] 10.1016/j.vaccine.2016.01.017. [PMID] 26802606.
2015
Conserved epitopes on HIV-1, FIV and SIV p24 proteins are recognized by HIV-1 infected subjects.
Human vaccines & immunotherapeutics. 11(6):1540-56 [DOI] 10.1080/21645515.2015.1026500. [PMID] 25844718.
2014
Feline immunodeficiency virus (FIV) vaccine efficacy and FIV neutralizing antibodies.
Vaccine. 32(6):746-54 [DOI] 10.1016/j.vaccine.2013.05.024. [PMID] 23800540.
2014
Pegylated feline granulocyte colony-stimulating factor increases neutrophil levels in cats.
Veterinary journal (London, England : 1997). 200(1):44-50 [DOI] 10.1016/j.tvjl.2014.01.019. [PMID] 24662027.
2014
Regulation of Somatostatin Receptor 4-Mediated Cytostatic Effects By Cd26 in Malignant Pleural Mesothelioma
British journal of cancer. 110(9):2232-2245 [DOI] 10.1038/bjc.2014.151. [PMID] 24743707.
2014
The Significance of Interferon-γ in HIV-1 Pathogenesis, Therapy, and Prophylaxis.
Frontiers in immunology. 4 [DOI] 10.3389/fimmu.2013.00498. [PMID] 24454311.
2013
Evolutionarily conserved epitopes on human immunodeficiency virus type 1 (HIV-1) and feline immunodeficiency virus reverse transcriptases detected by HIV-1-infected subjects.
Journal of virology. 87(18):10004-15 [DOI] 10.1128/JVI.00359-13. [PMID] 23824804.
2012
HIV-1 Vaccine Trials: Evolving Concepts and Designs.
The open AIDS journal. 6:274-88 [DOI] 10.2174/1874613601206010274. [PMID] 23289052.
2012
Utilization of feline ELISPOT for mapping vaccine epitopes.
Methods in molecular biology (Clifton, N.J.). 792:47-63 [DOI] 10.1007/978-1-61779-325-7_4. [PMID] 21956500.
2011
Evolutionarily conserved T-cell epitopes on FIV for designing an HIV/AIDS vaccine.
Veterinary immunology and immunopathology. 143(3-4):246-54 [DOI] 10.1016/j.vetimm.2011.06.019. [PMID] 21719117.
2010
Feline immunodeficiency virus model for designing HIV/AIDS vaccines.
Current HIV research. 8(1):14-25 [PMID] 20210778.
View on: PubMed
2010
Feline immunodeficiency virus model for designing HIV/AIDS vaccines.
Current HIV Research. 8(1) [DOI] 10.2174/157016210790416361. [PMID] 20210778.
2010
Identification of Cross-Reactive Fiv Epitopes as Potential Immunogens in An Hiv-1 Vaccine
Aids Research and Human Retroviruses. 26:A121-A122
2008
Advances in FIV vaccine technology.
Veterinary immunology and immunopathology. 123(1-2):65-80 [DOI] 10.1016/j.vetimm.2008.01.030. [PMID] 18295907.
2007
Feline immunodeficiency virus pathogenesis and development of a dual-subtype feline-immunodeficiency-virus vaccine.
AIDS (London, England). 21(5):547-63 [PMID] 17314517.
View on: PubMed
2007
Vaccine protection against feline immunodeficiency virus: setting the challenge.
Australian veterinary journal. 85(6):210-1 [PMID] 17547630.
View on: PubMed
2005
Dual-subtype FIV vaccine (Fel-O-Vax FIV) protection against a heterologous subtype B FIV isolate.
Journal of feline medicine and surgery. 7(1):65-70 [PMID] 15686976.
View on: PubMed
2005
FIV-infected cats respond to short-term rHuG-CSF treatment which results in anti-G-CSF neutralizing antibody production that inactivates drug activity.
Veterinary immunology and immunopathology. 108(3-4):357-71 [PMID] 16098604.
View on: PubMed
2005
HIV-1 p24 vaccine protects cats against feline immunodeficiency virus infection.
AIDS (London, England). 19(14):1457-66 [PMID] 16135898.
View on: PubMed
2004
Cellular immune responses to feline immunodeficiency virus (FIV) induced by dual-subtype FIV vaccine.
Vaccine. 23(3):386-98 [PMID] 15530685.
View on: PubMed
2003
Temporal dynamic changes in synthesis of chondroitin sulfate isomers in canine articular chondrocyte culture.
The Journal of veterinary medical science. 65(12):1373-6 [PMID] 14709831.
View on: PubMed
2002
FIV vaccine development and its importance to veterinary and human medicine: a review FIV vaccine 2002 update and review.
Veterinary immunology and immunopathology. 90(3-4):113-32 [PMID] 12459160.
View on: PubMed
2002
Is AZT/3TC therapy effective against FIV infection or immunopathogenesis?
Veterinary immunology and immunopathology. 85(3-4):189-204 [PMID] 11943320.
View on: PubMed
2001
Dual-subtype FIV vaccine protects cats against in vivo swarms of both homologous and heterologous subtype FIV isolates.
AIDS (London, England). 15(10):1225-37 [PMID] 11426067.
View on: PubMed
2001
Feline immunodeficiency virus lacks sensitivity to the antiviral activity of feline IFN-gamma.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research. 21(12):1039-46 [PMID] 11798461.
View on: PubMed
2001
Partial characterization of retroviruses from boid snakes with inclusion body disease.
American journal of veterinary research. 62(2):217-24 [PMID] 11212031.
View on: PubMed
2001
Phenotypic and functional characteristics of FIV infection in the bone marrow stroma.
Virology. 282(1):113-22 [PMID] 11259195.
View on: PubMed
2001
Quantitative analysis of chondroitin sulfate isomers in intervertebral disk chondrocyte culture using capillary electrophoresis.
The Journal of veterinary medical science. 63(9):1039-43 [PMID] 11642276.
View on: PubMed
2000
The use of human hematopoietic growth factors (rhGM-CSF and rhEPO) as a supportive therapy for FIV-infected cats.
Veterinary immunology and immunopathology. 77(1-2):71-92 [PMID] 11068067.
View on: PubMed
1999
MHC-restricted protection of cats against FIV infection by adoptive transfer of immune cells from FIV-vaccinated donors.
Cellular immunology. 198(1):30-43 [PMID] 10612649.
View on: PubMed
1998
Efficacy evaluation of prime-boost protocol: canarypoxvirus-based feline immunodeficiency virus (FIV) vaccine and inactivated FIV-infected cell vaccine against heterologous FIV challenge in cats.
AIDS (London, England). 12(1):11-8 [PMID] 9456250.
View on: PubMed
1998
Feline bone marrow transplantation: its use in FIV-infected cats.
Veterinary immunology and immunopathology. 65(2-4):323-51 [PMID] 9839883.
View on: PubMed
1998
Mechanism of HIV pathogenesis: role of superantigens in disease.
Alcoholism, clinical and experimental research. 22(5 Suppl):188S-192S [PMID] 9727632.
View on: PubMed
1997
Development of FIV-specific cytolytic T-lymphocyte responses in cats upon immunisation with FIV vaccines.
Veterinary microbiology. 57(1):1-11 [PMID] 9231977.
View on: PubMed
1997
Mechanism(s) of FIV vaccine protection.
Leukemia. 11 Suppl 3:98-101 [PMID] 9209311.
View on: PubMed
1997
Perspectives on FIV vaccine development.
Vaccine. 15(12-13):1437-44 [PMID] 9302758.
View on: PubMed
1996
HIV encodes for its own CD4 T-cell superantigen mitogen.
Biochemical and biophysical research communications. 225(2):672-8 [PMID] 8753817.
View on: PubMed
1995
Protection of neonatal kittens against feline immunodeficiency virus infection with passive maternal antiviral antibodies.
AIDS (London, England). 9(3):235-42 [PMID] 7755911.
View on: PubMed
1994
Superinfection of cats with feline immunodeficiency virus subtypes A and B.
AIDS research and human retroviruses. 10(12):1739-46 [PMID] 7888234.
View on: PubMed
1994
Tenth anniversary perspectives on AIDS. FIV as a model for AIDS vaccination.
AIDS research and human retroviruses. 10(3):225-8 [PMID] 8018382.
View on: PubMed

Grants

Feb 2018 – Dec 2019
MERCK/INTERVET ANIMAL CLINICAL VACCINE TRIAL
Role: Principal Investigator
Funding: INTERVET
Mar 2017 – Mar 2020
Identification of potent neutralizing Zika virus antibodies using single-cell analysis technology
Role: Co-Investigator
Funding: FL DEPT OF HLTH
Apr 2016 ACTIVE
Miscellaneous Donors Project 209
Role: Principal Investigator
Funding: MISCELLANEOUS DONORS
Jul 2013 – Jun 2017
The Structural and Functional Basis of HLA-associated Drug Hypersensitivity
Role: Project Manager
Funding: NATL INST OF HLTH NIAID

Patents

Issued March 2018
Cross-Reactive T Cell Epitopes of HIV, SIV and FIV for Vaccines in Humans and Cats (CIP)
#9,913,895
Published January 2018
Cross-Reactive T Cell Epitopes of HIV, SIV, and FIV for Vaccines in Humans and Cats (CON of CIP 15559)
#US-2018-0228890
Published October 2014
Materials and Methods for Detecting, Preventing and Treating Retroviral Infection (CON)
#US-2015-0098965
Issued April 2014
HIV Vaccine Against FIV Infection
#8,703,145
Issued May 2012
Method For Inducing Cross-Reactive Immune Responses To The Human Immunodeficiency Virus (HIV) In A Host By Administering Feline Immunodeficiency Virus (FIV) Capsid (CA) Or Reverse Transcriptase (RT) Immunogens
#8,182,820
Published May 2012
Materials and Methods for Detecting, Preventing and Treating Retroviral Infection (CON)
#US-2012-0294891
Issued February 2010
HIV Vaccine Against FIV Infection (CIP of 11089)
#7,658,927
Issued December 2007
Multi-Subtype FIV Vaccines
#7,311,921
Issued September 2007
Multi-Subtype FIV Vaccines
#7,267,824
Issued August 2003
Multi-Subtype FIV Vaccines
#6,605,282
Issued April 2003
MULTI-SUBTYPE FIV VACCINES
#6,544,528
Issued September 2002
Multi-Subtype FIV Vaccines (CON of 1385 ORD/UTIL)
#6,447,993
Published February 2002
MATERIALS AND METHODS FOR DETECTING, PREVENTING, AND TREATING OF RETROVIRAL INFECTIONS
#US-2003-0091987-A1
Issued July 2001
Multi-Subtype FIV Vaccines
#6,254,872
Issued October 1999
Retroviral Superantigens, Superantigen Peptides, and Methods of Use
#5,968,514
Issued December 1998
Feline-Derived T-Cell Lines for Producing FIV
#5,846,825
Issued May 1996
Retroviral Superantigens, Superantigen Peptides, and Methods of Use
#5,519,114

Education

PhD – Microbiology (Immunology)
1981 · The University of Texas Medical Branch, Galveston

Teaching Profile

Courses Taught
2009,2011-2020,2020
VME6905 Problems in Veterinary Medical Sciences
2020-2021
VME6934 Topics in Veterinary Medical Sciences
2018,2020
VME6464 Molecular Pathogenesis
2020
VME4906 Problems in Veterinary Science

Contact Details

Phones:
Business:
(352) 294-4145
Emails:
Business:
yamamoto@ufl.edu

University of Florida

IFAS

As part of both the Institute of Food and Agricultural Sciences and UF Health, Veterinary Medicine is dedicated to advancing animal, human and environmental health through teaching, research, extension and patient care.

IFAS

UNIVERSITY OF FLORIDA

Animal Hospitals

Need animal care? Visit the UF Small Animal and Large Animal Hospitals. From dogs, cats, birds and exotics to horses, cattle, llamas, pigs and many other large farm or food animals, our experienced veterinarian staff is ready to assist.

Animal Airwaves

Syndicated Podcast

Animal Airwaves

Animal Airwaves is a daily radio series that features one-minute segments relating to animal health, ranging from insights into animal behavior to veterinary patient care breakthroughs and trends.

Animal Airwaves